Viveve Medical Financial Statements (VIVE)
|
|
|
|
Report date
|
|
|
16.03.2018 |
15.03.2019 |
19.03.2020 |
18.03.2021 |
17.03.2022 |
|
10.11.2022 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
15.3 |
18.5 |
6.57 |
5.48 |
6.43 |
|
6.83 |
|
Operating Income, bln rub |
|
|
-33.7 |
-45.0 |
-29.9 |
-18.5 |
-21.6 |
|
-21.1 |
|
EBITDA, bln rub |
? |
|
-33.3 |
-44.2 |
-30.7 |
-19.3 |
-19.6 |
|
-20.4 |
|
Net profit, bln rub |
? |
|
-36.6 |
-49.2 |
-42.5 |
-21.9 |
-22.0 |
|
-23.9 |
|
|
OCF, bln rub |
? |
|
-34.9 |
-43.1 |
-31.2 |
-15.2 |
-12.9 |
|
-16.2 |
|
CAPEX, bln rub |
? |
|
0.905 |
2.14 |
1.09 |
0.781 |
0.456 |
|
0.595 |
|
FCF, bln rub |
? |
|
-35.8 |
-45.2 |
-32.3 |
-16.0 |
-13.3 |
|
-16.8 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.378 |
0.000 |
0.000 |
|
4.69 |
|
|
Ordinary share dividend yield, %
|
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
|
|
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
-19.6% |
|
|
OPEX, bln rub |
|
|
41.2 |
52.3 |
31.0 |
18.8 |
22.2 |
|
22.3 |
|
Cost of production, bln rub |
|
|
7.84 |
11.2 |
5.55 |
5.18 |
5.81 |
|
5.71 |
|
R&D, bln rub |
|
|
12.3 |
13.7 |
8.59 |
5.13 |
9.67 |
|
8.72 |
|
Interest expenses, bln rub |
|
|
3.17 |
4.37 |
4.35 |
0.910 |
1.000 |
|
1.11 |
|
|
Assets, bln rub |
|
|
36.1 |
46.8 |
27.0 |
16.6 |
25.9 |
|
12.2 |
|
Net Assets, bln rub |
? |
|
-2.60 |
4.91 |
16.5 |
6.97 |
15.1 |
|
1.18 |
|
Debt, bln rub |
|
|
28.9 |
30.5 |
4.25 |
5.99 |
5.35 |
|
5.88 |
|
Cash, bln rub |
|
|
20.7 |
29.5 |
13.3 |
6.52 |
19.2 |
|
5.91 |
|
Net debt, bln rub |
|
|
8.22 |
1.01 |
-9.06 |
-0.53 |
-13.8 |
|
-0.03 |
|
|
Ordinary share price, rub |
|
|
|
10 500 000 |
126 000 |
47 000 |
11 400 |
|
|
|
Number of ordinary shares, mln |
|
|
0.017 |
0.031 |
0.383 |
1.57 |
10.1 |
|
10.7 |
|
|
Market cap, bln rub |
|
|
0 |
326 120 |
48 287 |
73 956 |
115 023 |
|
0 |
|
EV, bln rub |
? |
|
8 |
326 121 |
48 278 |
73 955 |
115 009 |
|
0 |
|
Book value, bln rub |
|
|
-3 |
5 |
17 |
7 |
15 |
|
1 |
|
|
EPS, rub |
? |
|
-2 094 |
-1 584 |
-111.0 |
-13.9 |
-2.18 |
|
-2.24 |
|
FCF/share, rub |
|
|
-2 044 |
-1 456 |
-84.3 |
-10.2 |
-1.32 |
|
-1.58 |
|
BV/share, rub |
|
|
-148.6 |
158.2 |
43.1 |
4.43 |
1.49 |
|
0.11 |
|
|
EBITDA margin, % |
? |
|
-218.1% |
-238.5% |
-467.2% |
-352.7% |
-305.5% |
|
-299.2% |
|
Net margin, % |
? |
|
-239.6% |
-265.6% |
-647.6% |
-400.0% |
-342.8% |
|
-350.4% |
|
FCF yield, % |
? |
|
|
-0.01% |
-0.07% |
-0.02% |
-0.01% |
|
|
|
ROE, % |
? |
|
1 409% |
-1 001% |
-257.4% |
-314.2% |
-146.2% |
|
-2 020% |
|
ROA, % |
? |
|
-101.5% |
-105.0% |
-157.6% |
-131.8% |
-85.0% |
|
-196.8% |
|
|
P/E |
? |
|
0.00 |
-6 631 |
-1 135 |
-3 375 |
-5 222 |
|
0 |
|
P/FCF |
|
|
0.00 |
-7 210 |
-1 494 |
-4 618 |
-8 626 |
|
0 |
|
P/S |
? |
|
0.00 |
17 612 |
7 353 |
13 498 |
17 900 |
|
0 |
|
P/BV |
? |
|
0.00 |
66 392 |
2 923 |
10 605 |
7 635 |
|
0 |
|
EV/EBITDA |
? |
|
-0.25 |
-7 384 |
-1 574 |
-3 827 |
-5 858 |
|
0.00 |
|
Debt/EBITDA |
|
|
-0.25 |
-0.02 |
0.30 |
0.03 |
0.70 |
|
0.00 |
|
|
R&D/CAPEX, % |
|
|
1 364% |
640.3% |
790.2% |
656.2% |
2 120% |
|
1 466% |
|
|
CAPEX/Revenue, % |
|
|
5.92% |
11.6% |
16.6% |
14.3% |
7.10% |
|
8.72% |
|
| Viveve Medical shareholders |
